Luk Vandenberghe

Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA.

Albamunity, Inc. engages in the pharmaceutical business. The company is headquartered in Boston, MA.

Addgene, Inc. is a non-profit organization based in Watertown, MA that operates a biorepository for researchers. The non-profit company is based in Cambridge, MA. The company's collection contains over 100,000 plasmids contributed by more than 5,000 research labs worldwide. Addgene also provides over 700 ready-to-use AAV and lentivirus preparations of commonly requested plasmids as a service to scientists. The company has distributed over 1.6 million plasmids to 108 countries. Addgene is creating a lasting resource for research and discovery scientists around the world by authenticating, storing, archiving, and distributing plasmids, antibodies, viral vectors, and their associated data. The company offers educational resources such as ebooks, science guides, videos, and protocols.

Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.